Lifeward (NASDAQ:LFWD) Posts Quarterly Earnings Results

Lifeward (NASDAQ:LFWD) released its quarterly earnings results on Friday. The company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.07), FiscalAI reports. Lifeward had a negative net margin of 123.66% and a negative return on equity of 243.14%. The business had revenue of $6.62 million for the quarter, compared to the consensus estimate of $6.53 million.

Lifeward Price Performance

Shares of NASDAQ:LFWD traded down $0.44 on Friday, reaching $7.45. 16,937 shares of the company traded hands, compared to its average volume of 6,192. Lifeward has a fifty-two week low of $4.14 and a fifty-two week high of $10.56. The company’s 50 day moving average is $7.43 and its 200-day moving average is $6.99. The stock has a market capitalization of $21.08 million, a PE ratio of -0.38 and a beta of 0.38. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.40 and a quick ratio of 1.82.

Hedge Funds Weigh In On Lifeward

A number of hedge funds and other institutional investors have recently modified their holdings of LFWD. HRT Financial LP grew its stake in Lifeward by 149.7% during the 4th quarter. HRT Financial LP now owns 49,081 shares of the company’s stock valued at $28,000 after acquiring an additional 29,423 shares in the last quarter. Virtu Financial LLC increased its stake in Lifeward by 158.0% in the 4th quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock valued at $35,000 after buying an additional 37,037 shares during the period. Jane Street Group LLC lifted its position in Lifeward by 77.3% in the 4th quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock worth $40,000 after buying an additional 29,927 shares in the last quarter. Finally, Citadel Advisors LLC lifted its position in Lifeward by 1,271.8% in the 3rd quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock worth $152,000 after buying an additional 198,406 shares in the last quarter. Institutional investors and hedge funds own 26.76% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Weiss Ratings upgraded shares of Lifeward from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 3rd. Zacks Research raised Lifeward from a “strong sell” rating to a “hold” rating in a research note on Monday, July 27th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $10.00.

Lifeward Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.